Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.29%
#2 Ocean Protocol Ocean Protocol +18.64%
#3 KUB Coin KUB Coin +12.98%
#4 Audiera Audiera +10.79%
#5 Perle Perle +10.63%
#6 Wiki Cat Wiki Cat +9.96%
#7 Geodnet Geodnet +9.46%
#8 Arowana Arowana +9.35%
#9 OpenEden OpenEden +8.17%
#10 DexNet DexNet +7.78%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Frequency Therapeutics, Inc. Frequency Therapeutics, Inc.

Frequency Therapeutics, Inc.

FREQ
Rank in Stocks #32265
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company... Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments that unlock the body's inherent capacity for regeneration to restore impaired functions. Their "Progenitor Cell Activation" approach leverages small molecules to stimulate progenitor cells within the body, encouraging the formation of new, functional tissues. The company's flagship product candidate, FX-322, is currently in Phase IIa clinical trials, aiming to address the fundamental cause of sensorineural hearing loss. Beyond this, Frequency is also advancing therapies for various degenerative diseases, including multiple sclerosis, and ailments impacting muscles, the gastrointestinal system, skin, and bones. For the development and commercialization of FX-322, the company holds a license and collaboration agreement with Astellas Pharma Inc. Additionally, it maintains collaboration and licensing agreements with esteemed organizations such as Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Founded in 2014, Frequency Therapeutics, Inc. is headquartered in Lexington, Massachusetts.
Share Price
$0.2996
Last synced: 2023-11-03
Market Cap
$10.58M
Change (1 day)
5.94%
Change (1 year)
0.00%
Country
US
Trade Frequency Therapeutics, Inc. (FREQ)

Category

Healthcare
P/E ratio for Frequency Therapeutics, Inc. (FREQ)
P/E ratio as of 2026 TTM: 0
According to Frequency Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Frequency Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.